The INDICAR-Fellow Anne Conibear attended the 7th Chemical Protein Synthesis Meeting  that took place on Sept 4-7 in Haifa, Israel.  There, she presented her poster 'Synthetic Targeted Innate Immune Stimulators to Explore Avidity Effects', Anne Conibear, Andre Pötgens and Christian Becker. Well done Anne! 


The INDICAR-Fellow Nicola Silva presented yesterday his poster: “Interplay between BRCA1 and catabolism of ADP-ribose ensures crossover homeostasis and maintenance of genome integrity” at the EMBO Conference on Meiosis in Hvar, Croatia. Well done!


The INDICAR-Fellow Anne Conibear published in the journal Bioconjugate Chemistry: “Multifunctional αvβ6 integrin-specific peptide-Pt(IV) conjugates for cancer cell targeting”. Congratulations Anne!

Increasing the specificity of cancer therapy, and thereby decreasing damage to normal cells, requires targeting to cancer-cell specific features. The αvβ6 integrin is a receptor involved in cell adhesion and is frequently up-regulated in cancer cells compared to normal cells. We have selected a peptide ligand reported to bind specifically to the β6 integrin and have synthesized a suite of multispecific molecules to explore the potential for targeting of cancer cells. A combination of solid-phase peptide synthesis and chemoselective ligations was used to synthesize multifunctional molecules composed of integrin-targeting peptides, cytotoxic platinum(IV) prodrugs, and fluorescent or affinity probes joined with flexible linkers. The modular synthesis approach facilitates the construction of peptide–drug conjugates with various valencies and properties in a convergent manner. The binding and specificity of the multifunctional peptide conjugates were investigated using a cell line transfected with the β6 integrin and fluorescence microscopy. This versatile and highly controlled approach to synthesizing labeled peptide–drug conjugates has the potential to target potent cytotoxic drugs specifically to cancer cells, reducing the doses required for effective treatment.



Yesterday, two of our fellows gave talks at the Metallomics conference in Vienna. Kostas presented his research: “Restoring cellular sensitivity to platinum‐based drugs by targeted inhibition of STAT3” and Alessio: “Ruthenium arene complexes for G‐quadruplex DNA recognition”. Great job!!


Yesterday, our fellow Luca Tubiana presented his talk “Influence of Mutations on the Compactness of Viral ssRNA Genomes. A Detailed Computational Study of MS2 and BMV RNA2” at the Workshop on Physical Virology, organized by International Centre For Theoretical Physics of Unesco IAEA in Trieste (Italy).

You can watch Luca’s talk here.


The INDICAR-Fellow Mohamed Elgendy has co-authored the paper “PP2A Controls Genome Integrity by Integrating Nutrient-Sensing and Metabolic Pathways with the DNA Damage Response” published in the journal Molecular Cell. Congratulations!

Mec1ATR mediates the DNA damage response (DDR), integrating chromosomal signals and mechanical stimuli. We show that the PP2A phosphatases, ceramide-activated enzymes, couple cell metabolism with the DDR. Using genomic screens, metabolic analysis, and genetic and pharmacological studies, we found that PP2A attenuates the DDR and that three metabolic circuits influence the DDR by modulating PP2A activity. Irc21, a putative cytochrome b5 reductase that promotes the condensation reaction generating dihydroceramides (DHCs), and Ppm1, a PP2A methyltransferase, counteract the DDR by activating PP2A; conversely, the nutrient-sensing TORC1-Tap42 axis sustains DDR activation by inhibiting PP2A. Loss-of-function mutations in IRC21, PPM1, and PP2A and hyperactive tap42 alleles rescue mec1 mutants. Ceramides synergize with rapamycin, a TORC1 inhibitor, in counteracting the DDR. Hence, PP2A integrates nutrient-sensing and metabolic pathways to attenuate the Mec1ATR response. Our observations imply that metabolic changes affect genome integrity and may help with exploiting therapeutic options and repositioning known drugs.


On Monday 19th of June two INDICAR-Fellows, Cornelia Rumpf-Kienzl and Luca Tubiana, visited Sacre Coeur High School. They presented the 6A and 5E students their research in cancer and talked about everyday life of scientist as well. These talks developed the students’ interest in research careers. Thanks Sacre Coeur for having us, it was a great experience!


The INDICAR fellow Takahiko Akematsu just published the paper "Post-meiotic DNA double-strand breaks occur in Tetrahymena, and require Topoisomerase II and Spo11" in eLife. Congratulations!

Based on observations of markers for DNA lesions, such as phosphorylated histone H2AX (γH2AX) and open DNA ends, it has been suggested that post-meiotic DNA double-strand breaks (PM-DSBs) enable chromatin remodeling during animal spermiogenesis. However, the existence of PM-DSBs is unconfirmed, and the mechanism responsible for their formation is unclear. Here, we report the first direct observation of programmed PM-DSBs via the electrophoretic separation of DSB-generated DNA fragments in the ciliate Tetrahymena thermophila. These PM-DSBs are accompanied by switching from a heterochromatic to euchromatic chromatin structure in the haploid pronucleus. Both a topoisomerase II paralog with exclusive pronuclear expression and Spo11 are prerequisites for PM-DSB induction. Reduced PM-DSB induction blocks euchromatin formation, characterized by histone H3K56 acetylation, leading to a failure in gametic nuclei production. We propose that PM-DSBs are responsible for histone replacement during the reprogramming of generative to undifferentiated progeny nuclei.




Our fellow Antje Koller published the paper “Testing the Implementation of a Pain Self-Management Support Intervention for Oncology Patients in Clinical Practice: A randomized Controlled Pilot Study”, in the journal Cancer Nursing. Congratulations Antje!


Background: In oncology, pain control is a persistent problem. Significant barriers to cancer pain management are patient related. Pain self-management support interventions have shown to reduce pain intensity and patient-related barriers. Comparative effectiveness research is a suitable approach to test whether effects are sustained in clinical practice.

Objective: In this pilot randomized controlled trial, the implementation of the ANtiPain intervention into clinical practice was tested to assess the effects on pain intensity, function-related outcomes, self-efficacy, and patient-related barriers to pain management to prepare a larger effectiveness trial.

Methods: Within 14 months, 39 adult oncology patients with pain scores of 3 or higher on a 10-point numeric rating scale were recruited in an academic comprehensive cancer center in Southern Germany. Patients in the control group (n=19) received standard care. Patients in the intervention group (n=20) received ANtiPain, a cancer pain self-management support intervention based on 3 key strategies: provision of information, skill building, and nurse coaching. An intervention session was performed in-hospital. After discharge, follow-up was provided via telephone calls. Data were collected at baseline and 1 and 6 weeks after discharge. Effect sizes were calculated for all outcomes.

Results: Large effects were found for activity hindrance (Cohen d=0.90), barriers (d=0.91), and self-efficacy (d=0.90). Small to moderate effects were found for average and worst pain (Cohen d=0.17-0.45).

Conclusions: Key findings of this study involved function-related outcomes and self-efficacy.

Implications for Practice: Because these outcomes are particularly meaningful for patients, the integration of ANtiPain to routine clinical practice may be substantial. A larger study will be based on these findings.

MC Fellowship

Our fellow Alessio Terenzi was granted a Marie Curie fellowship under the H2020-MSCA-IF-2016 call. After he has finished his INDICAR fellowship, he is going to join Prof. Luca Salassa (Inorganic Photochemistry Lab) at the Donostia International Physics Center / University of The Basque Country (San Sebastian, Spain). Congratulations!


Alessio Terenzi published in the Journal Dalton Transactions: "Self-assembled Pt2L2 boxes strongly bind G-quadruplex DNA and influence gene expression in cancer cells"

Furthermore, Alessio Terenzi was awarded the front cover of the first issue of Dalton Transaction in 2017:


Mohamed Elgendy ( just published an article in the  Journal of Clinical Investigation (Impact Factor 13.2): "Dual modulation of MCL-1 and mTOR determines the response to sunitinib"

"In brief, the paper unravels mechanisms by which tumors adapt to and resist a drug called Sunitinib that's the first line therapy (best option) for renal cancer, making almost all the patients treated with this drug relapse within months. We also identified a clinical approach to make those tumors sensitive to this drug and potentially expand the lifespan of those patients."

This publication was also featured in one of the biggest newspapers in Italy:

INDICAR Workshop 2016

INDICAR - Workshop took place in Palermo, Italy, from Monday 12th Sept until Friday 16th Sept 2016.

The programme and timetable can be found on the webpage of the Workshop.



Our INDICAR fellow Alessio Terenzi just published the paper "Another step toward DNA selective targeting: NiII and CuII complexes of a Schiff base ligand able to bind gene promoter G-quadruplexes" in Dalton Transactions.

Abstract: DNA G-rich sequences are able to form four-stranded structures organized in stacked guanine tetrads. These structures, called G-quadruplexes, were found to have an important role in the regulation of oncogenes expression and became, for such a reason, appealing targets for anticancer drugs. Aiming at finding selective G-quadruplex binders, we have designed, synthesized and characterized a new water soluble Salen-like Schiff base ligand and its NiII and CuII metal complexes. UV-Vis, circular dichroism and FRET measurements indicated that the nickel complex can stabilize oncogene promoter G-quadruplexes with high selectivity, presenting no interactions with duplex DNA at all. The same compound exhibited dose-dependent cytotoxic activity in MCF-7 breast cancer cells when combined with lipofectamine as lipophilic carrier.


Two of our INDICAR fellows (Laura Cimatti and Anne Conibear) gave an interesting interview to the UNI:VIEW Magazin of the University of Vienna. Click here to read the interview (in German).